synthesis of a vasodilator PG that reduces the vasoconstriction.
~nhibition of PG synthesis would remove this vasodilator PG and, thus, increase the hypoxic constriction. Indirect evidence supporting this hypothesis in the neonate includes the observations that: 1) PGIa is the most abundant PG produced by fetal bovine pulmonary arterial slices (22) ; 2) under normoxic conditions, PGI? is the most abundant PG produced by the newly ventilated neonatal lamb lung (10, 11); 3) PG12 is a pulmonary vasodilator in the fetal and neonatal lamb (3, 9, 13) , and its vasodilatory effect on the neonatal pulmonary vasculature is more evident during hypoxic pulmonary vasoconstriction (13) ; and 4) hypoxic pulmonary vasoconstriction in premature and term neonatal goats is augmented by indomethacin, an inhibitor of PG synthesis (23) . In the present study, we used a neonatal lamb lung preparation perfused with Krebs' bicarbonate buffer to characterize and quantify prostanoids produced by the pulmonary vasculature from endogenous arachidonic acid in the absence of formed blood elements. Pulmonary perfusate was collected during ventilation with normoxic and hypoxic gas mixtures. Analysis of these perfusates allowed determination of the effect of hypoxic pulmonary vasoconstriction on pulmonary vascular prostanoid synthesis.
MATERIALS AND METHODS
Animalpreparation. Fourteen neonatal lambs [10.7 & 2.0 days old (SEM); 5.5 +. 1.6 kg) were anesthetized with 50 mg/kg achloralose IV. A tracheostomy was performed, and ventilation with room air was begun using a constant volume ventilator. A left thoracotomy was performed and the left lung was removed, leaving the mediastinum intact. Consequently, the right lung, which was to be perfused, was not exposed to the environment. The tidal volume was reduced by approximately 40%, the ductus arteriosus was ligated, and the left atrium was cannulated with a Teflon catheter. A repeat dose of 10 mg/kg a-chloralose was administered, and the pulmonary artery was ligated and cannulated, thus sacrificing the animal. Perfusion of the lung with 37°C Krebs' bicarbonate buffer, pH 7.4, containing 2 g glucose/liter equilibrated with 3% 0 ? , 5 % C02,92% Nq was then begun using a roller pump. The ventilating gas mixture was changed to 20% 02, 5% C02, 75% N2. The heart was clamped at the atrioventricular valves so that all perfusate exited through the left atrial catheter. The perfusate was not recirculated. During an initial 15-min equilibration period, formed elements cleared from the perfusate. A constant flow was maintained so that changes in pressure reflected changes in resistance. Flow was monitored electromagnetically. Pressure was monitored with a fluid-filled pressure transducer connected to a side arm of the inflow circuit just proximal to the pulmonary arterial catheter. Both signals were amplified and recorded with a direct-writing recorder.
Experimental protocol. After the 1 5-min equilibration period, pulmonary venous emuent was collected for 10 min. The ventilator gas mixture was then changed to 3% 02, 5% C02, 92% N2 reducing the pulmonary venous PO, from 85 to 33 mm Hg. One minute after the initiation of hypoxic ventilation, a second 10-min collection was begun. At the conclusion of this collection, the ventilating gas mixture was returned to 20% 0 2 , 5% C02, 75% NZ, and 10 min were allowed for return to normoxic conditions. Then a third 10-min collection was performed. The collected perfusates were stored at -60°C for later analysis.
Prostanoid analysis. The methods used are a modification of those which have been described and verified previously (8, 10) . Each sample was treated thusly. The pulmonary venous emuents were allowed to thaw and 600 ng PGAr were added to each as an internal standard. A sample containing 600 ng PGA2 and known amounts of PGE2, 6-keto-PGF,,,, TXB,, and 6,15-diketo-13,14-dihydro-PGF,,, (Upjohn) were processed with each set of samples. Following acidification to pH 3 with formic acid, each sample was applied to an octadecylsilyl cartridge (Sep-Pak, Waters Associates, Inc.) that previously had been washed and wetted with 30 ml acetone, 30 ml hexane, 60 ml methanol, and 60 ml of water. The Sep-Pak containing the sample was washed with 20 ml of water followed by 20 ml petroleum ether, both of which were discarded. The PGs were eluted with 10 ml of ethyl acetate [modified from Powell (1 6)]. Fifteen ml of toluene was added to the 10 ml of ethyl acetate and the mixture was applied to a silica column (Adsorbosil, 8 cm X 5 mm, Anspec, Inc.). PGs on the column were washed with 25 ml of 60:40 to1uene:ethyl acetate (discarded). PGs were eluted with 15 ml of 60:40:5: 1 toluene:ethyl acetate:methanol:formic acid. The eluant was evaporated under vacuum and the invisible residue was transferred to a reaction vial for derivatization prior to analysis by gas chromatography with electron capture detection. Derivatization to pentafluorobenzyloximes of PG methyl ester trimethylsilyl ethers was accomplished as described pewiously (8, 10) . Analyses were performed on a Perkin-Elmer Sigma 4, equipped with heated splitless injector and h3Ni electron capture detector. Gas-liquid chromatography was performed using 0.5 mm x 25 m SCOT OV 10 1 capillaries (Scientific Glass Engineering) at 250°C and a column pressure of 140 mm Hg, with helium as the camer. Injector and detector temperatures were 375°C.
Details and verification of methods used for quantification and mass spectrometric confirmation of derivatized standard structures have been published elsewhere (8) . Briefly, the relative detector responses to PGA2 and other PGs were determined from simultaneous extraction plus derivatization of known quantities of each. For each PC, a factor (8) encompassing all differences between PGs with respect to extraction, derivatization, and detector response, was calculated: 2 = ( W,. H,,)/(H,. w,), where W, is the quantity of PC.,, H., is the detector response to PC,, W,, is the quantity of PGA2, and H,, is the detector response to PGAr. PGs were quantified in the samples by comparison to PGA2 added as the internal standard: W, = H,. W, .
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This method (8, 10 ) is capable of quantifying as little as 5 ng of PGD2, PGE?, 6-keto-PGF,,,, TXB2, 6-keto-PGE,, or 6,15-diketo-13,14-dihydro-PGF,,, in the initial fluid sample.
Statistics. Results are reported as the mean * standard error of the mean for 14 animals. Hemodynamic data and PG production were analyzed using a two-way analysis of variance allowing partitioning of variation into that due to treatments (normoxia, hypoxia, normoxia), replications (14 animals), and residual variation. The F for the effect of treatments was defined as the mean square for treatments divided by the mean square for residuals with significance defined as P < 0.05. When the effect of treatments was significant, the mean value of a hemodynamic or PG variable during hypoxia was compared with the average of the pre-and posthypoxia means of that variable using the t-test for planned comparisons among means as described by Snedecor and Cochran (20) .
RESULTS
The results of these experiments are illustrated in Figure 1 . Constant flow was maintained throughout each experiment, the mean flow being 2.2 f 0.3 ml/min.kg body weight or 11.2 + + 0.9 mm Hg/(ml/kgmin) during hypoxia, returning to 4.9 f 0.9 mm Hg/(ml/kg. min) with return to normoxia. PG12 synthesis, measured as 6-ketoPGF,,, increased significantly from 6.4 + 2.7 ng/min during normoxic ventilation to 14.3 f 5.4 ng/min during hypoxia and returned to 4.7 k 1.2 ng/min with resumption of normoxia. A metabolite of PGI,, co-migrating on the gas chromatographic column with synthetic 6,15-diketo-13,14-dihydro PGF,,,, was detected sporadically and in concentrations far less than that of 6-keto-PGF,,,. Thromboxane A2 (as thromboxane B-) was the only other prostanoid detected, and its synthesis did not change significantly with alveolar hypoxia (2.8 12, 23, 24, 27, 28) in several species including newly ventilated and several-day-old neonatal goats (23) . Augmentation of hypoxic pulmonary vasoconstriction following prostaglandin cyclooxygenase inhibition suggests that either alveolar hypoxia is associated with increased synthesis of a vasodilator PG by the pulmonary vasculature which blunts hypoxic pulmonary vasoconstriction or that cyclooxygenase inhibition diverts arachidonic acid to the lipoxygenase pathway causing increased synthesis of a vasoconstrictor leukotriene.
PGI, is a potent pulmonary vasodilator in the perinatal period (3, 9, 13) and is the major PG synthesized from endogenous arachidonic acid by the perinatal pulmonary vasculature under normoxic conditions (10, 11) . The present study demonstrates that hypoxic pulmonary vasoconstriction is associated with an increased synthesis of PGIr from endogenous substrate in the neonatal lamb pulmonary vasculature. These data are consistent with previous studies showing that PG synthesis inhibition augments hypoxic pulmonary vasoconstriction, probably by inhibiting the synthesis of the vasodilator PG, PG12. Further, the ability of cyclooxygenase inhibitors to block the pulmonary vasoconstrictor response to exogenous arachidonic acid (6, 12) seems to argue against an important role of a vasoconstrictor leukotriene in the regulation of pulmonary vascular resistance.
Initial efforts by other workers at demonstrating the presence of and identifying a vasodilator PG employed classical tissue cascade bioassay techniques and radioimmunoassays of PGE and PGF2,, (19, 25, 29) . Augmentation of PG synthesis by hypoxic pulmonary vasoconstriction was not detected in these studies. The radioimmunoassays used would not have detected PGI,. Furtnermore, although PGI2 was first identified by bioassay, the small quantities of PG12 produced by the pulmonary vasculature and the spontaneous hydrolysis of PGIl to 6-keto-PGF,,, to which bioassay tissue respond poorly, may have hindered thedetection of PG12 by the bioassay tissues. Supporting this idea are the observations of Mullane et al.
( 1 5 ) that infusions of arachidonic acid cause pulmonary vasodilation due to bioassayable PG12; infusion of arachidonic acid would allow for synthesis of considerably more PG12 by the pulmonary vasculature than could be produced from endogenous arachidonic acid and thus would facilitate detection of PG12 by bioassay.
The techniques employed in the present study were designed to allow detection and quantification of the small quantities of PGI, produced by the pulmonary vasculature from endogenous arachidonic acid by collecting all of the pulmonary perfusate over 10-min periods and concentrating the PGs thus collected.
Voelkel et al. (26) infused radioactively labeled arachidonic acid into perfused adult rat lungs, thus labeling the endogenous arachidonic acid pool. They subsequently measured increased release of the radioactive label with hypoxic pulmonary vasoconstriction and identified PG12 as the major labeled PG. Hamasaki et al. (4) found that hypoxia stimulates PGI2 synthesis from endogenous arachidonic acid in homogenates of adult dog lung. These results are consistent with those of the present study performed on neonatal lamb lungs.
Effects of arachidonic acid, the precursor of PG12 and thromboxane A,, on hypoxic pulmonary vasoconstriction have been variable with both dilation (2) and further constriction (6) described depending upon the experimental circumstances. Infusion of large quantities of exogenous arachidonic acid per unit time into the pulmonary circulation has a vasoconstrictor effect (5, 7, 12) and augments the constriction caused by alveolar hypoxia (6) or by 15-methyl-PGFz,, (21) . On the other hand, Spannhake et al. (21) were able to produce pulmonary vasodilation by slowly infusing small quantities of arachidonic acid when pulmonary vascular tone was increased with either hypoxia or 15-methyl-PGFz,,. Slow infusion of arachidonic acid may allow for more complete conversion of the precursor to PG12 without producing excessive vasoconstrictor cyclic endoperoxides and rhromboxane Az. Thus, Gerber et al. (2) reported that slow arachidonic acid infusion reduces hypoxic pulmonary vasoconstriction and identified PGIz in the pulmonary venous effluent. These observations are consistent with the results of the present study.
Rubin and Lazar (17) have reported recently that inhibition of hypoxic pulmonary vasoconstriction by hydralazine is prevented by indomethacin. Their data are consistent with ours but suggest that alveolar hypoxia alone does not stimulate prostacyclin synthesis maximally, since hydralazine appears to further reduce hypoxic pulmonary vasoconstriction by a PG-mediated mechanism.
Recently, Moon et al. (14) were able to reduce hypoxic pulmonary vasoconstriction in adult dogs by infusing arachidonic acid, and they detected an increase in the ratio of aortic to pulmonary arterial PGI2 concentration. However, these workers were unable to detect a change in PG12 synthesis from endogenous substrate during alveolar hypoxia. This latter result differs from our own and could represent species or age differences.
In summary, the present study demonstrates that hypoxia stimulates pulmonary vascular synthesis of PG12 from endogenous substrate in neonatal lambs. These findings suggest that the augmentation of hypoxic pulmonary vasoconstriction by prostaglandin cyclooxygenase inhibition is due, at least in part, to interference with the synthesis of this vasodilator prostanoid.
